Gmax Biopharm
PrivateLast Round
Series C
Mar 9, 2021
Est. Valuation
$80.52M
Total Funding Raised
$92.22M
Company Overview
Gmax Biopharm operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series C round in March 2021.
Gmax Biopharm is a biopharmaceutical company that develops innovative therapeutic monoclonal antibodies targeting G-protein coupled receptors (GPCRs) for the treatment of cardiovascular, metabolic, and cancer-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gmax Biopharm Comparables
Compare Gmax Biopharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QL Biopharm | 87% | |
| Zhejiang Doer Biologics | 86% | |
| Sino Biopharmaceutical | 80% |
For institutional investors. Book with your work email.
Gmax Biopharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 9, 2021 | ||||
| Series B | Jan 22, 2017 | ||||
| Series A | Dec 28, 2014 | ||||
| Angel | Sep 1, 2010 |
For institutional investors. Book with your work email.
Gmax Biopharm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Merchants Group | Series C |
| Zhongyuan Capital | Series C |
| Lechuanghui | Series A |
| Efung Capital | Series B |
| Cowin Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 2, 2026
Monthly visitors grew 3197% MoM, reaching 5.3K.
- Jun 1, 2025
Monthly visitors increased 68% MoM, reaching 1K.
For institutional investors. Book with your work email.
Gmax Biopharm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gmax Biopharm's valuation, stock price, and market status.
Is Gmax Biopharm a public or private company?
Gmax Biopharm is a private company.
What is the current stock price of Gmax Biopharm?
Gmax Biopharm is a private company, so its shares have no public market price. Caplight tracks Gmax Biopharm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gmax Biopharm worth (valuation)?
Gmax Biopharm's valuation is estimated at $80.5M based on funding round data.
Can I buy Gmax Biopharm stock?
Gmax Biopharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gmax Biopharm's last funding round?
Gmax Biopharm's most recent funding round was Series C on March 9, 2021.
Who are the main investors in Gmax Biopharm?
Key investors in Gmax Biopharm include China Merchants Group.
Will Gmax Biopharm IPO soon?
No public IPO plans have been announced for Gmax Biopharm.
How can I track Gmax Biopharm secondary market activity?
Caplight tracks bids, offers, and trades in Gmax Biopharm's shares on secondary markets.